Literature DB >> 26481952

Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials.

Adnan M Nagrial1, Venessa T Chin2, Katrin M Sjoquist3, Marina Pajic4, Lisa G Horvath5, Andrew V Biankin6, Desmond Yip7.   

Abstract

There remains uncertainty regarding the optimal second-line chemotherapy in advanced pancreatic ductal adenocarcinoma (PDAC). The current recommendation of 5-fluorouracil and oxaliplatin may not be relevant in current practice, as FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) has become a more popular first line therapy in fit patients. The majority of studies in this setting are single-arm Phase II trials with significant heterogeneity of patient populations, treatments and outcomes. In this review, we sought to systematically review and synthesise all prospective data available for the second-line treatment of advanced PDAC.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Pancreatic cancer; Second-line; Systematic review; Trials

Mesh：

Year:  2015        PMID： 26481952     DOI： 10.1016/j.critrevonc.2015.07.007

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


  14 in total

Review 1.  Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA).

Authors:  M Uccello; M Moschetta; G Mak; T Alam; C Murias Henriquez; H-T Arkenau
Journal:  Curr Oncol       Date:  2018-02-28       Impact factor: 3.677

Review 2.  Harnessing the Immune System in Pancreatic Cancer.

Authors:  Satya Das; Jordan Berlin; Dana Cardin
Journal:  Curr Treat Options Oncol       Date:  2018-08-20

Review 3.  Pancreatic adenocarcinoma: Beyond first line, where are we?

Authors:  Sara Cherri; Silvia Noventa; Alberto Zaniboni
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

Review 4.  Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM).

Authors:  Nicola Silvestris; Oronzo Brunetti; Alessandro Bittoni; Ivana Cataldo; Domenico Corsi; Stefano Crippa; Mirko D'Onofrio; Michele Fiore; Elisa Giommoni; Michele Milella; Raffaele Pezzilli; Enrico Vasile; Michele Reni
Journal:  Cancers (Basel)       Date:  2020-06-24       Impact factor: 6.639

Review 5.  Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives.

Authors:  Wonhee Woo; Edward T Carey; Minsig Choi
Journal:  Onco Targets Ther       Date:  2019-02-21       Impact factor: 4.147

6.  Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.

Authors:  Rachna T Shroff; Andrew Hendifar; Robert R McWilliams; Ravit Geva; Ron Epelbaum; Lindsey Rolfe; Sandra Goble; Kevin K Lin; Andrew V Biankin; Heidi Giordano; Robert H Vonderheide; Susan M Domchek
Journal:  JCO Precis Oncol       Date:  2018-05-16

Review 7.  Chemotherapy and radiotherapy for advanced pancreatic cancer.

Authors:  Venessa Chin; Adnan Nagrial; Katrin Sjoquist; Chelsie A O'Connor; Lorraine Chantrill; Andrew V Biankin; Rob Jpm Scholten; Desmond Yip
Journal:  Cochrane Database Syst Rev       Date:  2018-03-20

8.  Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma.

Authors:  Angela Zaccagnino; Antonella Managò; Luigi Leanza; Artur Gontarewitz; Bernhard Linder; Michele Azzolini; Lucia Biasutto; Mario Zoratti; Roberta Peruzzo; Karen Legler; Anna Trauzold; Holger Kalthoff; Ildiko Szabo
Journal:  Oncotarget       Date:  2017-06-13

9.  Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study.

Authors:  Jung Hoon Kim; Sang-Cheol Lee; Sung Yong Oh; Seo-Young Song; Namsu Lee; Eun Mi Nam; Soonil Lee; In Gyu Hwang; Hyo Rak Lee; Kyu Taek Lee; Sang-Byung Bae; Han Jo Kim; Joung Soon Jang; Do Hyoung Lim; Hyun Woo Lee; Seok Yun Kang; Jung Hun Kang
Journal:  Cancer Commun (Lond)       Date:  2018-06-04

Review 10.  From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer.

Authors:  Andrés Muñoz Martín; Manuel Hidalgo; Rafael Alvarez; Virginia Arrazubi; Joaquina Martínez-Galán; Mercedes Salgado; Teresa Macarulla; Alfredo Carrato
Journal:  J Cancer       Date:  2018-04-30       Impact factor: 4.207
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.